Corcept Therapeutics Incorporated (Nasdaq: CORT) 34.4% LOWER; Announced that the second of its three Phase 3 trials evaluating CORLUX for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE